Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant Still Holding Off On DTC Ads For Controversial Female Sex Pill

This article was originally published in The Pink Sheet Daily

Executive Summary

The female libido enhancing drug Addyi (flibanserin) has drawn a lot of attention, but the sponsor is making less of a splash with the launch.

You may also be interested in...



Female Libido Booster Found In Supplements: Health And Wellness Industry News

Addyi ingredient found in Organic Herbal Supply products; FDA, Australia recognize food safety systems as comparable; and researchers show B vitamins could have a role in reducing the impact of air pollution on the epigenome.

In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication

Panel’s vote to approve Sprout’s female sexual dysfunction drug is conditioned on a REMS and possible contraindication with alcohol use; questions about drug’s date rape potential, breast cancer finding in mice addressed.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel